- cancer vaccines
Immunicum AB (publ) develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Immunicum’s products can be produced cost efficiently in large scale.
The therapeutic cancer vaccine INTUVAX® is injected intratumorally and has recently been evaluated in a finalized clinical Phase I/II-study in metastatic renal cell carcinoma showing promising survival data and clear indications of tumor specific immune activation. INTUVAX® utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely standardized therapeutic cancer vaccine that is still able to offer a personalized treatment and store in frozen condition for long periods of time.
Immunicum is a biopharmaceutical company that was founded in 2002 as a spinoff from Sahlgrenska University Hospital, in Gothenburg, Sweden
Immunicum has three different platforms for the development of cancer immunotherapies
Immunicum has four ongoing projects, with a strong focus on the ongoing clinical trial in renal cell carcinoma
Press releases, financial reports, calendar, meetings/presentations, etc.
Date changedRead more